<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047474</url>
  </required_header>
  <id_info>
    <org_study_id>1306012255</org_study_id>
    <secondary_id>NCI-2013-02349</secondary_id>
    <secondary_id>1306012255</secondary_id>
    <secondary_id>P30CA016359</secondary_id>
    <nct_id>NCT02047474</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well combination chemotherapy before and after surgery works&#xD;
      in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as&#xD;
      leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller&#xD;
      and reduce the amount of normal tissue that needs to be removed. Giving these treatments&#xD;
      after surgery may kill any tumor cells that remain after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the progression-free survival in patients with resectable non-metastatic&#xD;
      pancreatic cancer treated with peri-operative modified leucovorin calcium, fluorouracil,&#xD;
      irinotecan hydrochloride, oxaliplatin (mFOLFIRINOX).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine overall survival. II. Determine objective response rate after neoadjuvant&#xD;
      mFOLFIRINOX.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Compare R0 resection rate and pathologic stage with institutional historical controls who&#xD;
      did not receive neoadjuvant therapy.&#xD;
&#xD;
      II. Correlate early metabolic response, determined by changes in glucose metabolism using&#xD;
      positron emission tomography (PET) scanning, with pathologic response, R0 resection, and&#xD;
      pathologic stage.&#xD;
&#xD;
      III. Correlate early metabolic response, determined by changes in glucose metabolism using&#xD;
      PET scanning, with progression-free and overall survival.&#xD;
&#xD;
      IV. Correlate pre-operative response of CA19-9 with progression-free and overall survival.&#xD;
&#xD;
      V. Collect and bank serial serum and plasma specimens from subjects for future correlative&#xD;
      biomarker studies.&#xD;
&#xD;
      VI. Collect and bank tumor tissue from subjects prior to treatment (from the diagnostic&#xD;
      endoscopic ultrasonography [EUS]-guided biopsy) and after treatment with six cycles of&#xD;
      FOLFIRINOX (from the surgical specimen) for future correlative biomarker studies.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin intravenously (IV)&#xD;
      over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90&#xD;
      minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2&#xD;
      weeks for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo&#xD;
      surgical resection.&#xD;
&#xD;
      ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as&#xD;
      in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 months for 3 years,&#xD;
      every 6 months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 25, 2014</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>At 12 months</time_frame>
    <description>Evaluated using a one-sided 0.10-alpha level exact test. Summarized using Kaplan-Meier curves</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Summarized using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Acinar Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Duct Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Stage I Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.&#xD;
ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (mFOLFIRINOX)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic or cytologic documentation of pancreatic adenocarcinoma&#xD;
&#xD;
          -  Resectable pancreatic adenocarcinoma disease as defined as follows:&#xD;
&#xD;
               -  No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or&#xD;
                  laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or&#xD;
                  distant metastases;&#xD;
&#xD;
               -  No evidence of tumor extension to superior mesenteric artery, hepatic artery,&#xD;
                  celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or&#xD;
                  encasement of the superior mesenteric vein or superior mesenteric vein/portal&#xD;
                  vein confluence, as assessed by computed tomography (CT) using pancreatic&#xD;
                  protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT)&#xD;
                  and EUS&#xD;
&#xD;
          -  No prior treatment (chemotherapy, biological therapy, or radiotherapy) for resectable&#xD;
             pancreatic cancer&#xD;
&#xD;
          -  No prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride),&#xD;
             fluorouracil or capecitabine&#xD;
&#xD;
          -  Patients who received chemotherapy &gt; 5 years ago for malignancies other than&#xD;
             pancreatic cancer are eligible&#xD;
&#xD;
          -  There is no evidence of the second malignancy at the time of study entry&#xD;
&#xD;
          -  &gt; 4 weeks since major surgery&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0-1&#xD;
&#xD;
          -  No other malignancy within past five years except basal cell carcinoma of the skin,&#xD;
             cervical carcinoma in situ, or non-metastatic prostate cancer&#xD;
&#xD;
          -  Paraffin block or slides must be available&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
             lung&#xD;
&#xD;
          -  No &gt;= grade 2 sensory peripheral neuropathy&#xD;
&#xD;
          -  No uncontrolled seizure disorder, active neurological disease, or known central&#xD;
             nervous system (CNS) disease&#xD;
&#xD;
          -  No significant cardiac disease, including the following: unstable angina, New York&#xD;
             Heart Association class II-IV congestive heart failure, myocardial infarction within&#xD;
             six months prior to study enrollment&#xD;
&#xD;
          -  No history of chronic diarrhea&#xD;
&#xD;
          -  Not pregnant and not nursing&#xD;
&#xD;
          -  No other medical condition or reason that, in the opinion of the investigator, would&#xD;
             preclude study participation&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 X upper limit of normal (ULN) or&#xD;
&#xD;
          -  Estimated glomerular filtration rate (GFR) &gt; 30 ml/min&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 X ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3 X ULN&#xD;
&#xD;
          -  Negative pregnancy test in women of childbearing age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Lacy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Fairfield</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Guilford</name>
      <address>
        <city>Guilford</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at St. Francis Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at North Haven</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Orange</name>
      <address>
        <city>Orange</city>
        <state>Connecticut</state>
        <zip>06477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Torrington</name>
      <address>
        <city>Torrington</city>
        <state>Connecticut</state>
        <zip>06790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Trumbull</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Waterbury</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

